Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q3 2016 call → NOWe need answer YES/NO based on transcript. Need determine if management describes counterparties already losing something real and ongoing for as long as they do not have what company provides, and that behavior reflects it. Company: Fate Therapeutics. Programs: ProTmune for HCT, FATE-NK100, ToleraCyte, iPSC platform. Which counterparties? Patients? Partners? Juno collaboration? Need see. Question: "ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS THEY DO NOT HAVE WHAT THIS COMPANY PROVIDES, and that this accumulating loss on the other side is ALREADY VISIBLE in how those parties are behaving toward the company today?" Essentially a running meter on customer/partner side. For ProTmune, patients undergoing HCT suffer GvHD, infections, relapse. That is ongoing loss? But are those counterparties? Patients waiting? The company developing therapy. Management describes unmet need, morbidity/mortality. But is there behavior by counterparties indicating they are pressing? They opened sites, regulatory designations. Not necessarily. For FATE-NK100: IND filed, collaboration with University of Minnesota. Not about counterparties losing. For iPSC: partnership with MSKCC. Not. Maybe Juno collaboration revenue. No. Need answer based only transcript. Management doesn't describe customers/partners already losing because they go without product. They describe patients with unmet need, but no behavior of patients acting. Regulatory designations Fast Track etc. not counterparties losing. So NO. Need be careful: The transcript mentions "substantial unmet need" and "patients die/relapse" but that's not counterparty behavior. Also "seeking regulatory guidance" not. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...